363 related articles for article (PubMed ID: 23047041)
21. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
22. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
[TBL] [Abstract][Full Text] [Related]
23. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
24. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Beier D; Schriefer B; Brawanski K; Hau P; Weis J; Schulz JB; Beier CP
J Neurooncol; 2012 Aug; 109(1):45-52. PubMed ID: 22544650
[TBL] [Abstract][Full Text] [Related]
26. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
[TBL] [Abstract][Full Text] [Related]
27. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
[TBL] [Abstract][Full Text] [Related]
28. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Munoz JL; Rodriguez-Cruz V; Greco SJ; Ramkissoon SH; Ligon KL; Rameshwar P
Cell Death Dis; 2014 Mar; 5(3):e1145. PubMed ID: 24675463
[TBL] [Abstract][Full Text] [Related]
29. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
30. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
31. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
32. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Ding Y; Zhang C; He L; Song X; Zheng C; Pan Y; Yu S
Bioengineered; 2021 Dec; 12(2):10791-10798. PubMed ID: 34753395
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
34. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Anderson JC; Duarte CW; Welaya K; Rohrbach TD; Bredel M; Yang ES; Choradia NV; Thottassery JV; Yancey Gillespie G; Bonner JA; Willey CD
Radiother Oncol; 2014 Jun; 111(3):468-74. PubMed ID: 24813092
[TBL] [Abstract][Full Text] [Related]
35. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
[TBL] [Abstract][Full Text] [Related]
36. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
37. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728
[TBL] [Abstract][Full Text] [Related]
38. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Munoz JL; Walker ND; Scotto KW; Rameshwar P
Cancer Lett; 2015 Oct; 367(1):69-75. PubMed ID: 26208431
[TBL] [Abstract][Full Text] [Related]
40. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
